Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 6/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22537676 | 0.94 | L3MBTL1 (0.43) | L3MBTL1APPNOX1POLBCYBB | |
| SCHEMBL14921136 | 0.82 | ALDH1A1 (0.52) | L3MBTL1APPNOX1POLBMAPT | |
| SCHEMBL6643854 | 0.80 | L3MBTL1 (0.47) | L3MBTL1APPNOX1POLBCYBB | |
| SCHEMBL2549477 | 0.80 | APP (0.42) | APPMAPTMEN1KMT2A | |
| SCHEMBL194538 | 0.80 | ALDH1A1 (0.48) | L3MBTL1APPNOX1POLBCYBB | |
| SCHEMBL8650234 | 0.78 | L3MBTL1 (0.46) | L3MBTL1NOX1POLBMAPTKMT2A | |
| SCHEMBL1537864 | 0.78 | ALDH1A1 (0.50) | L3MBTL1APPNOX1POLBCYBB | |
| SCHEMBL5853973 | 0.78 | L3MBTL1 (0.46) | L3MBTL1APPNOX1POLBCYBB | |
| Hydrochloric Acid SCHEMBL9661413 | 0.78 | L3MBTL1 (0.46) | L3MBTL1APPNOX1POLBCYBB | |
| SCHEMBL29426388 | 0.78 | APP (0.41) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20210382060-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | Shanghai Glory Capital Management Ltd. (CN) | 2021-12-09 | — | — | US | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-06-20 | — | — | US | disclosed |
| WO-2018055316-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | HNRNPF, HNRNPUL2, RAB5IF | L3MBTL1 616/4885APP 2001/4885NOX1 4532/4885 |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | HNRNPF, HNRNPUL2, RAB5IF | L3MBTL1 616/4885APP 2001/4885NOX1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.